Short-Term Effectiveness and Tolerability of Vigabatrin Therapy in Infantile Epileptic Spasms Syndrome

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology

Background:

• Infantile Epileptic Spasms Syndrome (IESS) is a severe epilepsy syndrome in infants.
• Treatment options for IESS can be limited, especially for cases resistant to hormonal therapies.

Purpose of the Study:

• To evaluate the short-term effectiveness and tolerability of vigabatrin in children diagnosed with IESS.
• To determine the rate of complete cessation of epileptic spasms (ES) and the incidence of adverse events associated with vigabatrin therapy.

Main Methods:

• Prospective follow-up of 107 children with IESS initiated on vigabatrin therapy for up to 12 weeks.
• Assessment of complete cessation of ES for at least four weeks and monitoring for adverse events.
• Analysis of demographic and etiological factors, including structural etiology and sex.

Main Results:

• Thirty percent of children achieved complete cessation of ES for at least four weeks.
• The median effective dose was 95 mg/kg/d, with 84.4% of responders achieving cessation within two weeks.
• Relapse occurred in 12.5% of patients, and 13% experienced adverse events, most commonly drowsiness (9.3%).

Conclusions:

• Vigabatrin demonstrates modest short-term clinical effectiveness in treating children with hormonal-therapy-resistant IESS.
• The drug is generally well-tolerated in this pediatric population, with drowsiness being the primary adverse event.
• Early cessation of spasms within two weeks suggests prompt therapeutic benefit for many patients.